In the Spotlight
Read MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer in Molecular Cancer Therapeutics. Paclitaxel, a chemotherapeutic agent that induces cell death via microtubule arrest, is the standard of care for metastatic triple-negative breast cancer, however response rates vary, and resistance often develops. In this article, Oudin and colleagues report a novel mechanism of resistance to paclitaxel. Expression of pro-metastatic splice variants of the actin regulator Mena allows tumor cells to proliferate, invade and metastasize during Paclitaxel treatment by promoting microtubule dynamics and survival signaling. Paclitaxel treatment also elevates Mena protein levels in vitro and in vivo. These results may lead to improved biomarkers and therapeutic strategies for use of paclitaxel to treat metastatic disease.
Read the article by Daniel Pietrasz, et al: Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker, recently published in Clinical Cancer Research and covered in an AACR press release.
New! Read the recently released CEBP Focus: The Obesity Paradox in Cancer: Evidence and New Directions, by editors, Electra Paskett and Bette Caan. Find out more about the Journal, Cancer Epidemiology, Biomarkers & Prevention.